

EMA/85849/2018

European Medicines Agency decision

P/0046/2018

of 16 February 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (ABT-494) (EMEA-001741-PIP03-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0046/2018

of 16 February 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (ABT-494) (EMA-001741-PIP03-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by AbbVie Ltd on 24 October 2016 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 January 2018, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for upadacitinib (ABT-494), tablet, age-appropriate oral pharmaceutical form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for upadacitinib (ABT-494), tablet, age-appropriate oral pharmaceutical form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver upadacitinib (ABT-494), tablet, age-appropriate oral pharmaceutical form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Road, SL6 4UB – Maidenhead, United Kingdom.

EMA/PDCO/757426/2017

London, 26 January 2018

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001741-PIP03-16

Scope of the application

Active substance(s):

Upadacitinib (ABT-494)

Condition(s):

Treatment of Crohn's Disease

Pharmaceutical form(s):

Tablet

Age-appropriate oral pharmaceutical form

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

AbbVie Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted for agreement to the European Medicines Agency on 24 October 2016 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 29 November 2016.

Supplementary information was provided by the applicant on 3 November 2017. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Crohn's disease

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- tablet, age-appropriate oral pharmaceutical form, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of Crohn's disease (CD)

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with moderately to severely active Crohn's disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Tablet

Age-appropriate oral pharmaceutical form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Age-appropriate oral solid dosage form (dispersible tablet or multi-particulate granules) or age-appropriate oral liquid dosage form.
Non-clinical studies	2	Study 2 Dose range-finding juvenile toxicity study. Study 3 Definitive juvenile toxicity study to evaluate toxicity and impact of upadacitinib on neonatal/juvenile development.

Clinical studies	1	Study 4 Double-blind safety, efficacy, and pharmacokinetic study with an open label induction phase of upadacitinib in children from 2 to less than 18 years with moderately to severely active Crohn's disease, who have had an inadequate response or been intolerant to corticosteroids, immunosuppressants, and/or biologic therapy, or have medical contraindications to such therapies. (M14-671).
Extrapolation, modelling and simulation studies	1	Study 5 Population PK modelling and simulation study to determine the dose of upadacitinib in children from 2 to less than 18 years of age with Crohn's disease.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By January 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes